Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock ...

Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Amgen (AMGN) closed at $434.03 in the latest trading session, marking a +1.86% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.33%. Meanwhile, the Dow ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Amgen stock recently closed at USD 385.65 on Nasdaq on September 18, 2026, leaving it close to the average analyst target near USD 387.69. Recent quarters have seen strong earnings momentum, ...

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.